Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

DISEASE CHARACTERISTICS: * Confirmed diagnosis of one of the following: * Primary acute myeloid leukemia (AML) meeting any of the following criteria: * First complete remission (CR; defined as \< 5% blasts in marrow) with high-risk features as defined by failure to achieve remission by day 21 after induction chemotherapy, or the presence of chromosomal abnormalities involving any of the following: * -5/del(5q) * -7/del(7q) * Inversion 3q * Abnormalities of 11q23, 20q, 21q, del(9q), * Translocation 6;9 * Translocation 9;22 * Abnormalities of 17p * Complex karyotype with ≥ 3 abnormalities * Second CR or subsequent in remission * Refractory or relapsed disease * Secondary AML in remission or relapse * Chronic myelogenous leukemia (CML) in accelerated or blast phase meeting the following criteria: * Accelerated phase is defined by any one of the following: * Blasts 10% to 19% of peripheral blood white cells or bone marrow cells * Peripheral blood basophils ≥ 20% * Persistent thrombocytopenia (\< 100,000/mm³) unrelated to therapy, or persistent thrombocytosis (\> 1,000,000/mm³) unresponsive to therapy * Increasing spleen size and increasing WBC count unresponsive to therapy * Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase CML) * Blast …